左西孟旦联合缬沙坦对慢性心力衰竭患者心肌损伤标志物的影响

Effect of levosimendan combined with valsartan on myocardial injury markers in patients with chronic heart failure

目的探讨左西孟旦联合缬沙坦对慢性心力衰竭患者心肌损伤标志物的影响。方法回顾性分析2018年1月至2020年1月本院的98例慢性心力衰竭患者的临床资料,根据治疗方法将患者分为联合治疗组(n=49,左西孟旦联合缬沙坦治疗)与单独治疗组(n=49,左西孟旦单独治疗)。比较两组的心功能指标、临床疗效、血清心肌损伤标志物水平及不良反应发生情况。结果治疗后,联合治疗组的SV、LVEF均高于单独治疗组(P<0.05)。联合治疗组的治疗总有效率高于单独治疗组(P<0.05)。治疗后,两组的血清NT-proBNP、cTnT、cTnI水平均降低,血清IGF-1水平均升高,且联合治疗组均优于单独治疗组(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论左西孟旦联合缬沙坦治疗慢性心力衰竭的效果显著,可有效减轻患者心肌损伤,改善心功能。

Objective To explore the effect of levosimendan combined with valsartan on myocardial injury markers in patients with chronic heart failure.Methods The clinical data of 98 patients with chronic heart failure in our hospital from January 2018 to January 2020 were retrospectively analyzed.According to the treatment methods,the patients were divided into combined treatment group(n=49,treated with levosimendan combined with valsartan)and single treatment group(n=49,treated with levosimendan alone).Cardiac function indexes,clinical efficacy,serum myocardial injury markers level and adverse reactions were compared between the two groups.Results After treatment,SV and LVEF in the combined treatment group were higher than those in the single treatment group(P<0.05).The total effective rate of treatment in the combined treatment group was higher than that in the single treatment group(P<0.05).After treatment,the serum NT-proBNP,cTnT,cTnI levels in the two groups decreased,and the serum IGF-1 level increased,and those in the combined treatment group were better than the single treatment group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Levosimendan combined with valsartan in the treatment of patients with chronic heart failure has significant effect,it can effectively reduce myocardial injury and improve cardiac function of patients.